Consensus Charles River Laboratories International, Inc.
Equities
CRL
US1598641074
Biotechnology & Medical Research
|
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 184.31 USD | +0.15% |
|
+3.46% | -0.16% |
Evolution of the Average Target: Charles River Laboratories International, Inc.
Evolution of the Target Price: Charles River Laboratories International, Inc.
Changes in Analyst Recommendations: Charles River Laboratories International, Inc.
| Consensus | Analysts' recommendations evolution (4 months) | Financial estimates divergence | Analysts' Target price divergence | Objective/dr gap | ||
|---|---|---|---|---|---|---|
 | +2.69% | |||||
| +25.03% | |||||
| +10.69% | |||||
| +24.35% | |||||
| +21.91% | |||||
| -1.74% | |||||
| +1.9% | |||||
| +10.93% | |||||
| +19.25% | |||||
| +4.64% | |||||
| Average | +11.96% | |||||
| Weighted average by Cap. | +15.53% |
Analysts' Consensus
Analyst Consensus Detail
Consensus revision (last 18 months)
Analysts covering the company
| Jefferies & Co. | |
| Argus | |
| Morgan Stanley | |
| TD Cowen | |
| JPMorgan Chase | |
| Barclays | |
| Baird | |
| BofA Securities | |
| Mizuho Securities | |
| Deutsche Bank Securities | |
| William Blair & Co. | |
| Evercore ISI | |
| Rothschild & Co Redburn | |
| Citigroup | |
| Redburn Atlantic | |
| UBS | |
| Goldman Sachs | |
| Stephens Inc. | |
| Barrington Research | |
| Zacks Investment Research | |
| Guggenheim | |
| Wells Fargo Securities | |
| Credit Suisse | |
| KeyBanc Capital Markets | |
| Truist Securities | |
| J.P. Morgan Chase |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Global Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Global Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite), and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of the rankings based on the following ratings: Capital Efficiency (Composite), Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully review the associated descriptions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- CRL Stock
- Consensus Charles River Laboratories International, Inc.
Select your edition
All financial news and data tailored to specific country editions
MarketScreener is also available in this country: United States.
Switch edition